08189 TEDA BIOMEDICAL
- 0.068
- -0.006-8.11%
TEDA BIOMEDICAL News
泰達生物：二零二三年年報
Teda Biotech (08189) proposes to appoint Tu Xiangzhen as an independent non-executive director
Teda Biotech (08189) announced that Mr. Li Xudong has resigned as an independent non-executive director and will no longer serve on the company's audit committee...
TEDA BIOMEDICAL: ANNOUNCEMENT ON ANNUAL RESULTS FOR 2023
Teda Biotech (08189.HK) plans to sell 82.76% of Shanghai Weidi's shares for 10.593 million yuan
Gelonghui, March 27, 丨 Teda Biotech (08189.HK) announced that on January 31, 2024, the company signed an equity transfer agreement. Based on this, the company agreed to sell 82.76% of Shanghai Weidi's shares to the buyer at a cost of RMB 10.593 million. After completion, the company will still hold 17.24% of Shanghai Weidi's shares. In view of Shanghai Weidi's performance over the past two years and uncertainty about future prospects, the board of directors believes that the sale is a good opportunity for the company to monetize its investment in Shanghai. Additionally, considering the proceeds from the sale, the company is able to reallocate its resources to its existing
Teda Biotech (08189): Qin Wenhua Resigns as Co-CEO
Zhitong Finance App News, Teda Biotech (08189) issued an announcement. Qin Wenhua has resigned as Co-CEO due to busy affairs and other personal reasons, effective March 26, 2024.
Huatai Securities: The silver economy may spawn a series of investment opportunities from the capital side, demand side, and supply side
As China's aging deepens, the introduction of the first banking economic policy may spawn a series of investment opportunities from the demand side, supply side, and capital side.
Demand for spring farming led to a rebound in the urea market and repair profit margins, but far from the previous year|Industry News
① Spring cultivation and preparation for cultivation have been carried out one after another. Many urea manufacturers, such as Hualu Hengsheng, Sichuan Meifeng, Liuguo Chemical, and Lutianhua, raised the ex-factory price of urea products by about 50 yuan to 60 yuan/ton, and the price increase of urea prices was nearly 8% in the past month; ② Under high supply, urea prices were only 80% of the same period last year, and the profit margin was less than the same period last year.
Ministry of Civil Affairs: Increase the supply of old-age services and cultivate new forms of old-age services
Li Yongxin, head of the Department of Elderly Care Services of the Ministry of Civil Affairs, said at a press conference that in the next step, the Ministry of Civil Affairs will increase the supply of old-age services. Develop meal aid services for the elderly, guide all regions to implement action plans to actively develop meal aid services for the elderly, innovate organizational forms, service models and operating mechanisms for the elderly, and continuously expand the scope and improve quality and efficiency on a sustainable basis.
TEDA BIOMEDICAL: Third Quarterly Report 2023
Teda Biotech (08189) released the first three quarter results, losses attributable to shareholders of 17.2942 million yuan narrowed 20.03% year-on-year
Teda Biotech (08189) announced its results for the third quarter of 2023. The group achieved revenue from continuing operations during the period...
TEDA BIOMEDICAL: ANNOUNCEMENT ON THIRD QUARTERLY RESULTS FOR 2023
TEDA BIOMEDICAL: Interim Report 2023
TEDA BIOMEDICAL: ANNOUNCEMENT ON HALF-YEARLY RESULTS FOR 2023
TEDA Biotech (08189) concludes a final settlement agreement with Hong Kong's TEDA, SJK and SJKGC
According to the Zhitong Finance App, Teda Biotech (08189) announced that on August 1, 2023, the company, Hong Kong TEDA, SJK and SJKGC signed a final settlement agreement on these agreements. The main terms are set out as follows: 1. The contracting party confirmed that since SJKGC failed to satisfactorily fulfill mechanism 1 and mechanism 2 under the revised and re-arranged shareholders' agreement and supplementary share purchase agreement, mechanism 3 (payment of minimum guaranteed cash dividends and stock refund) has been automatically implemented, while the mechanism under 3 companies has taken the proper receipt Minimum guaranteed cash dividends. 2. The contracting party further agreed to the public
TEDA BIOMEDICAL: NOTICE OF BOARD OF DIRECTORS'' MEETING
TEDA BIOMEDICAL: First Quarterly Report 2023
Teda Biotech (08189.HK)'s consolidated turnover of 86.42 million yuan in the first quarter decreased 3.11% year-on-year
Glonghui, May 10, 丨 Teda Biotech (08189.HK) announced that for the three months ending March 31, 2023, the Group achieved a consolidated turnover of RMB 86.42 million, a decrease of 3.11% over the previous year. The loss attributable to the company's equity owners was RMB 5,8766 million (2022/3/31: loss of RMB 6.043,500); the company lost RMB 0.310 per share compared to RMB 0.319 per share for the same period last year. The Board does not recommend dividends for the three months ending March 31, 2023. The Group is currently involved in two major businesses
TEDA BIOMEDICAL: ANNOUNCEMENT ON FIRST QUARTERLY RESULTS FOR 2023
TEDA BIOLOGY: 2022 ANNUAL REPORT
Teda Biotech (08189) announces 2022 results, shareholders' attributable loss of 28.106 million yuan narrowed 33.48% year on year
According to the Zhitong Finance App, Teda Biotech (08189) disclosed its 2022 annual results announcement. The company achieved an annual turnover of 450 million yuan (RMB, same below), a year-on-year decrease of 5.61%. The gross profit was 16.395,000 yuan, a year-on-year decrease of 64.05%. Shareholders accounted for a loss of 28.106 million yuan, and the loss narrowed 33.48% year on year. During the reporting period, the company's comprehensive gross margin was 3.67%, compared to 9.57% in the same period last year; the main reason for the significant decline in annual comprehensive gross margin was that factors related to the first half of the year significantly boosted international energy and commodity raw materials, including high levels of imported potassium and their
Analysis
Price Target
No Data
